<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060290</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-KAL-AE-01</org_study_id>
    <nct_id>NCT04060290</nct_id>
  </id_info>
  <brief_title>Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, Prospective, observational study，to evaluate the safety and
      influencing factors of albumin-bound paclitaxel in the real-world chinese population，and
      evaluate of the efficacy of albumin-bound paclitaxel in patients with recurrent or metastatic
      breast cancer and its impact on quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage and severity of Participants With Adverse Events (AEs)</measure>
    <time_frame>28 days after the end of the last chemotherapy cycle</time_frame>
    <description>percentage and CTC AE(v4.0) of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)</measure>
    <time_frame>From signing informed consent，assessed up to end of study (up to approximately 24months)</time_frame>
    <description>ORR is defined as the rate of CR or PR, as determined by IRC using RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate patients' quality of life by the European Cancer Research and Treatment Tissue Cancer Quality Core Questionnaire EORTCQLQ-C30</measure>
    <time_frame>From signing informed consent，assessed up to end of study (up to approximately 24months)</time_frame>
    <description>EORTC QLQC30 scale was used to score the quality of life before treatment, at each chemotherapy cycle, and at the end of treatment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Observational study of this study, no interventions involved</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Recurrent or metastatic breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In patients with breast cancer who have been treated with albumin-bound paclitaxel for
             the treatment of metastatic breast cancer who failed to undergo chemotherapy or who
             have relapsed within 6 months after adjuvant chemotherapy, unless there is a clinical
             contraindication, the previous chemotherapy regimen must include an a anthracycline
             drug

        Exclusion Criteria:

          -  No
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Zhao</last_name>
    <role>Study Director</role>
    <affiliation>Shiyao Group Ouyi Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li guohui</last_name>
    <phone>010-67714970</phone>
    <email>zlyyliguohui@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei Dong</last_name>
    <phone>0451-86298568</phone>
    <email>13804567370@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Sun yancai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shen aizong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tumor Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Mei Dong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhang wenzhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Autonomous Region Cancer Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bai zaixian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liu Guangxuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li guohui</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

